Kraj: Unia Europejska
Język: angielski
Źródło: EMA (European Medicines Agency)
Ketoconazole
HRA Pharma Rare Diseases
J02AB02
ketoconazole
Antimycotics for systemic use
Cushing Syndrome
Ketoconazole HRA is indicated for the treatment of endogenous Cushing’s syndrome in adults and adolescents above the age of 12 years.
Revision: 10
Authorised
2014-11-18
31 B. PACKAGE LEAFLET 32 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT KETOCONAZOLE HRA 200 MG TABLETS ketoconazole This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects. READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Ketoconazole HRA is and what it is used for 2. What you need to know before you take Ketoconazole HRA 3. How to take Ketoconazole HRA 4. Possible side effects 5. How to store Ketoconazole HRA 6. Contents of the pack and other information 1. WHAT KETOCONAZOLE HRA IS AND WHAT IT IS USED FOR Ketoconazole HRA is a medicine that contains the active substance ketoconazole with an anticorticosteroid activity. It is used to treat endogenous Cushing’s syndrome (when the body produces an excess of cortisol) in adults and adolescents above the age of 12 years. Cushing’s syndrome is caused by overproduction of a hormone called cortisol which is produced by the adrenal glands. Ketoconazole HRA is able to block the activity of the enzymes responsible for the synthesis of cortisol and consequently is able to decrease the over-production of cortisol by your body and to improve the symptoms of Cushing’s syndrome. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE KETOCONAZOLE HRA _ _ DO NOT TAKE KETOCONAZOLE HRA - if you are allergic to ketoconazole and/or to any imidazole antifungal medicine, or to any of the other ingredients of t Przeczytaj cały dokument
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Ketoconazole HRA 200 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 200 mg ketoconazole. Excipient with known effect: Each tablet contains 19 mg of lactose (as monohydrate). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet. Off-white to light cream, round, 10 mm diameter, biconvex. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Ketoconazole HRA is indicated for the treatment of endogenous Cushing’s syndrome in adults and adolescents above the age of 12 years. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Treatment should be initiated and supervised by physicians experienced in endocrinology or internal medicine and having the appropriate facilities for monitoring of biochemical responses since the dose must be adjusted to meet the patient’s therapeutic need, based on the normalisation of cortisol levels. Posology _Initiation _ The recommended dose at initiation in adults and adolescents is 400-600 mg/day taken orally in two or three divided doses and this dose can be increased rapidly to 800-1,200 mg/day in two or three divided doses. At treatment initiation, 24-hour urinary free cortisol should be controlled every few days/weeks. _ _ _Adjustment of the posology _ Ketoconazole daily dose should be periodically adjusted on an individual basis with the aim to normalise urinary free cortisol and/or plasma cortisol levels. - A dose increase of 200 mg/day every 7 to 28 days may be considered if urinary free cortisol and/or plasma cortisol levels are above the normal range, as long as the dose is tolerated by the patient; 3 - A maintenance dose from 400 mg/day to a maximal dose of 1,200 mg/day taken orally in 2 to 3 divided do Przeczytaj cały dokument